Table 4.

Studies reported sensitivity, specificity, PPV, and NPV for each ASGE predictor

Predictor	Study	n	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
US with stone	Yang et al. [31]	926	35.7	97.9	58.1	94.9
	He et al. [21]	524	44	97	91	73
	Kuzu et al. [22]	285	36.6	85.3	90.5	26
	Jagtap et al. [16]	174	62	99.6	98.3	87.9
	Aleknaite et al. [28]	137	51.3	84.6	86.2	48.3
	Magalhaes et al. [18]	109	55.9	89.9	91.7	50.3
	Bose et al. [32]	88	50	97	87	82
	Adams et al. [13]	65	21.8	93.5	70.8	62.3
	Nárvaez Rivera et al. [14]	44	23	91	77	48
	Rubin et al. [19]	43	13	98	88	47
	Suarez et al. [24]	13	14.1	97.1	76.9	61.9
Acute cholangitis	He et al. [21]	463	20	84	44	61
	Videhult et al. [17]	323	22	70	9	88
	Lee et al. [29]	184	32.4	69.6	59.8	42.4
	Kuzu et al. [22]	154	18.9	88.6	86.3	22.1
	Bose et al. [32]	88	42	100	100	80
	Jagtap et al. [16]	71	22.8	99	88.7	78.1
	Nárvaez Rivera et al. [14]	37	19	92	76	47
	Magalhaes et al. [18]	36	18.4	96.6	91.7	37
	Rubin et al. [19]	23	7	98	83	45
Tbli > 4 mg/dL	He et al. [21]	349	22	94	69	65
	Kuzu et al. [22]	210	25.2	82.6	84.7	22.4
	Rubin et al. [19]	167	41	79	72	51
	Nárvaez Rivera et al. [14]	151	61	44	59	47
	Lee et al. [29]	113	20	81.5	60.2	42.1
	Magalhaes et al. [18]	102	42.5	70.8	74.5	37.8
	Suarez et al. [24]	37	29.6	84.3	56.8	63.2
	Chan et al. [33]	19	39	95	93	44
Tbli 1.8–4 mg/dL	Rubin et al. [19]	172	32	63	54	43
	Kuzu et al. [22]	164	19.5	85.3	83.5	21.6
	Lee et al. [29]	158	25.9	71.2	55.7	40.71
	Magalhaes et al. [18]	84	61.1	66.6	75	51.2
	Nárvaez Rivera et al. [14]	66	25	73	55	53
CBD > 6 mm	He et al. [21]	1419	75	63	57	79
	Kuzu et al. [22]	780	70.9	23.9	82	70.4
	Jagtap et al. [16]	434	69.9	68.5	44.5	86.4
	Lee et al. [29]	368	73.8	51.9	68.2	58.6
	Rubin et al. [19]	260	58	61	66	53
	Aleknaite et al. [28]	209	92.5	32.2	71.3	70.2
	Magalhaes et al. [18]	195	83.8	49.4	76.9	60.3
	Nárvaez Rivera et al. [14]	193	82	33	62	59
ALFT	He et al. [21]	1657	77	50	50	77
	Kuzu et al. [22]	612	71.1	39.6	81.8	26.4
	Rubin et al. [19]	499	98	7	57	68
	Lee et al. [29]	451	73.2	16.9	55.2	31.1
	Nárvaez Rivera et al. [14]	254	99	1	57	50
	Magalhaes et al. [18]	231	89.9	21.3	69.7	51.3
	Jagtap et al. [16]	205	90.2	38.5	34.6	91.6
Age > 55	He et al. [21]	1408	60	54	46	67
	Kuzu et al. [22]	609	69.6	35.3	80.4	23.3
	Lee et al. [29]	351	65	46.5	62.3	48.7
	Jagtap et al. [16]	205	37	69.5	30.4	75.4
	Magalhaes et al. [18]	197	79.3	38.2	72.1	47.9
	Rubin et al. [19]	86	18	86	63	45
	Nárvaez Rivera et al. [14]	81	37	85	65	47
Acute pancreatitis	Jagtap et al. [16]	408	23.2	55.9	15.7	66.6
	He et al. [21]	310	10	85	29	59
	Kuzu et al. [22]	135	13.6	78.8	71.1	19.3
	Rubin et al. [19]	134	22	69	48	41
	Videhult et al. [17]	130	21	90	20	90
	Lee et al. [29]	107	15	77	47.7	39.3
	Bose et al. [32]	88	12	96	60	72
	Nárvaez Rivera et al. [14]	80	20	54	36	34
	Magalhaes et al. [18]	63	20.1	69.7	57.1	30.2
	Adams et al. [13]	57	41.7	68.9	43.9	67
	Suarez et al. [24]	56	55.6	76.3	52.6	78.4
Tbli > 4 mg/dL  +  CBD > 6 mm	He et al. [21]	267	19	96	78	58

Sample sizes reported were relevant sample sizes, as not all studies had samples comprised entirely of (suspected) CDL patients